EX-32.1 5 ye2021-ex321.htm EX-32.1
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Pliant Therapeutics, Inc. (the “Company”) on Form 10-K for the period ending December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 28, 2022 | /s/ Bernard Coulie
| Bernard Coulie, M.D., Ph.D.
| President and Chief Executive Officer
| (Principal Executive Officer)
| /s/ Keith Cummings
| Keith Cummings, M.D., MBA
| Chief Financial Officer
| (Principal Financial Officer)